Dr. Elie G. Dib, MD

Dr. Dib practices at IHA Hematology Oncology Consultants in Ann Arbor, Michigan.

Dr. Dib's NPI, 1174576219, was assigned on May 18, 2006. Dr. Dib holds Michigan license 4301105914.

Dr. Dib's primary practice is IHA Hematology Oncology Consultants, at 24 Frank Lloyd Wright Dr, Ann Arbor, MI 48105 in Washtenaw County. The practice phone is (734) 712-1000.

Dr. Dib's primary practice is IHA Hematology Oncology Consultants in Ann Arbor, Michigan. Dr. Dib is also affiliated with Trinity Health Ann Arbor Hospital. The medical group on file is Trinity Health IHA Medical Group. Dmand AI also links Dr. Dib to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dib practices, 5 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Dib's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Dib is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Dib's licenses on file in 4 states: Michigan, South Dakota, New York and Massachusetts.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), immune deficiency disease, lung cancer and lymphoma among the conditions Dr. Dib treats.

CMS data shows 1,076 Medicare services from Dr. Dib across 9 procedure codes in 2024, for 302 Medicare patients. Medicare paid $87,912 for them.

CMS counts 302 Medicare patients who saw Dr. Dib in 2024. The largest group is 65 to 74, with 123 patients. 75% of them have high blood pressure, and 68% have high cholesterol. 10% are also on Medicaid. Their average risk score is 1.98, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dib's median patient age at 73, with 56% women.

In 2024, Dr. Dib wrote 1,874 Medicare Part D claims for 307 patients. 76% of them were for generic drugs. CMS names the drug for 1,660 of them, across 41 drugs with 11 or more claims each, at $5,128,072 in total drug cost. In 2023, CMS named 1,476 claims across 34 drugs.

Dr. Dib accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Dib as offering telehealth.

Dmand AI links 18 papers to Dr. Dib, published from 2008 to 2024. 2024 was the busiest year, with 3. The most frequent topics are Antineoplastic Agents, Geriatric Assessment and Antibodies, Monoclonal, Humanized. Dr. Dib has published most often in JCO Precis Oncol. Dr. Dib's most frequent co-authors are Supriya Gupta Mohile, MD, Nicholas J. Vogelzang, MD and Eugene R. Ahn, MD.

Dmand AI links Dr. Dib to 23 clinical trials, 9 of them phase 2 studies. 15 are still active or recruiting. Conditions studied include Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasm Metastasis and Leukemia, B-Cell. Alliance for Clinical Trials in Oncology sponsors the most, 6.

CMS Open Payments shows 5 general payments to Dr. Dib from 4 drug and device companies from 2019 to 2024. Food and beverage make up the largest share, 89% of the total. Abbott Laboratories paid the most, $168.

Dmand AI lists 1 award for Dr. Dib, most recently CMS Stage 1 EHR in 2013.

Dr. Dib is a member of American Association of Cancer Research, ACP, ASCO, ASH and Society for Immunotherapy of Cancer (SITC).

Dr. Dib is in network with 11 carriers, including Aetna, Health Alliance Plan and Priority Health. HMO plans come from the most carriers, 6. Check the plan with the practice before a visit.